



April 1, 2021

To,

✓ **National Stock Exchange of India Ltd.**

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Stock Code: LUPIN

Dear Sir/ Madam,

BSE Ltd.

Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Stock Code: 500257

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We wish to inform you that DigiHealth Technologies LLP, the wholly owned entity of our investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), has agreed to acquire 100% ownership interest in Pharmarack Technologies Private Limited in tranches. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFO/CMD/4/2015 dated 9th September 2015, are given in **Annexure 'A'** to this letter.

We request you to kindly take this in your record and disseminate.

Thanking you,

For LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Personal,
2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29a5f004
91762a5ac549cb034cae, postalCode=400104, st=Maharashtra,
serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f7
26cdb67a2ff09c4242771b2a, cn=Rajvardhan Vishnu Satam
Date: 2021.04.01 18:26:58 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl.: - Annexure 'A'

ANNEXURE 'A'

Details as per Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015: -

Sr. No.	Particulars	Detail
a.	Name of the target entity, details in brief such as size, turnover etc.	<p>(i) Name of the Target Entity:</p> <p>Pharmarack Technologies Private Limited ("Pharmarack").</p> <p>(ii) Details of the Target Entity:</p> <p>Pharmarack operates a digital platform aimed at integrating and solving problems across the pharmaceutical supply chain. Its platform offers/proposes to offer products across supply chain including order automation, fulfilment services & optimization, digital payments, working capital optimization, analytics and market insights.</p>
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is one at 'arms-length'.	Not a related party transaction.
c.	Industry to which the entity being acquired belongs.	Healthcare Industry.
d.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line' of business of the listed entity).	A step by ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) towards the initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India (' Business '). The acquisition is and will be done by its wholly owned entity DigiHealth Technologies LLP.
e.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
f.	Indicative time period for completion of the acquisition.	<p>The upfront acquisition of 91.8% of shareholding in Pharmarack is expected to be completed within a period of 30 (thirty) days by purchase of shares from multiple existing shareholders in various lots.</p> <p>The remaining 8.2% of the shareholding in Pharmarack is likely to be acquired in multiple tranches over the next 5 (five) years.</p>

g.	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash Consideration payable by DigiHealth Technologies LLP.
h.	Cost of acquisition or the price at which the shares are acquired.	Cost of acquisition to DigiHealth Technologies LLP for upfront acquisition of 91.8% is INR 111 crores. Cost of acquisition of remaining shareholding shall be linked to future performance of Pharmarack.
i.	Percentage of shareholding / control acquired and / or number of shares acquired.	Please refer to the response provided in point f. above.
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	<p>(i) About the entity:</p> <p>Pharmarack operates a digital platform aimed at integrating and solving problems across the pharmaceutical supply chain. Its platform offers/ proposes to offer products across supply chain including order automation, fulfilment services & optimization, digital payments, working capital optimization, analytics and market insights.</p> <p>(ii) Date of Incorporation:</p> <p>September 21, 2015</p> <p>(iii) Turnover history of last 3 years:</p> <p>2019-2020: INR 4,04,52,773/- 2018-2019: INR 2,14,87,907/- 2017-2018: INR 64,90,444/-</p> <p>(iv) Country:</p> <p>India</p>